glp-1 weight gain A Comprehensive Review on following Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity - Abdullah bin Ahmed - 2024 - Journal of Obesity GLP-1 Agonists In Obesity

Recently, ten human patients with lumbar IVD disease treated with an intradiscal BMSC injection showed diminished pain and disability and a significantly elevated IVD water content (MRI) at the 1-year follow-up [98]

A typical summary might read: You do not need to remember what to say the journal has already drafted it for you

MT-1 (Afamelanotide) induces skin pigmentation and MC1R-mediated photoprotection that physically and biologically shields the skin from the phototoxic light wavelengths activating protoporphyrin

The development of GLP-1 analogues like semaglutide has ushered in a new era of obesity treatment, offering hope to millions struggling with weight management and related health issues

doi: 10.2337/dc08-2124